Literature DB >> 2299810

Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement.

R Schindler1, G Lonnemann, S Shaldon, K M Koch, C A Dinarello.   

Abstract

Stimulation of interleukin-1 beta (IL-1 beta) and tumor necrosis factor (TNF alpha) production was studied during in vitro hemodialysis (HD) of whole blood using cuprammonium (Cup) or polysulfone (PS) dialyzers. In the absence of LPS, circulation of whole blood for two hours through Cup or PS dialyzers was not sufficient to induce production of IL-1 beta or TNF alpha in peripheral blood mononuclear cells (PBMC) during subsequent 24 hour culture. However, compared to freshly isolated cells, post-HD PBMC were primed to produce more IL-1 beta and TNF alpha when subsequently stimulated with LPS. Despite the lack of spontaneous monokine synthesis after HD, we observed transcription of mRNA coding for IL-1 beta and TNF alpha after two hours of LPS-free HD. When compared to levels of mRNA induced by 5 ng/ml LPS (100%), Cup induced 27 +/- 6% whereas PS did not induce detectable transcription of IL-1 beta. In the case of TNF alpha mRNA, Cup induced 26 +/- 8% and PS 13 +/- 3%. Recombinant C5a induced mRNA for IL-1 beta in PBMC without detectable IL-1 beta protein synthesis. We conclude that transcription of mRNA for IL-1 beta and TNF alpha during HD is primarily caused by complement activation by Cup, but that LPS or other factors are required for translation of IL-1 beta and TNF alpha mRNA transcribed during HD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299810     DOI: 10.1038/ki.1990.12

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Enhanced susceptibility to subcutaneous abscess formation and persistent infection around catheters is associated with sustained interleukin-1beta levels.

Authors:  J J Boelens; S A Zaat; J L Murk; J J Weening; T van Der Poll; J Dankert
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Alterations in mononuclear cell tumour necrosis factor-alpha (TNF-alpha) response in patients on long term cuprophane haemodialysis.

Authors:  A Y Annenkov; A G Strokov; F S Baranova
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

3.  Granulocyte-macrophage colony-stimulating factor amplification of interleukin-1beta and tumor necrosis factor alpha production in THP-1 human monocytic cells stimulated with lipopolysaccharide of oral microorganisms.

Authors:  A A Baqui; T F Meiller; J J Chon; B F Turng; W A Falkler
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

4.  Interleukin-1 receptor type I gene-deficient mice are less susceptible to Staphylococcus epidermidis biomaterial-associated infection than are wild-type mice.

Authors:  J J Boelens; T van der Poll; S A Zaat; J L Murk; J J Weening; J Dankert
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

5.  The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1.

Authors:  H Montz; K C Koch; R Zierz; O Götze
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

6.  Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2.

Authors:  Oliver Weinmann; Ralf Gutzmer; Jörg Zwirner; Miriam Wittmann; Katja Langer; Margarete Lisewski; Susanne Mommert; Alexander Kapp; Thomas Werfel
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

7.  Reactive oxygen product formation by human neutrophils as an early marker for biocompatibility of dialysis membranes.

Authors:  A R Rosenkranz; E Templ; O Traindl; H Heinzl; G J Zlabinger
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

8.  Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis.

Authors:  Elisabeth C Samouilidou; Eirini J Grapsa; Ioannis Kakavas; Antonios Lagouranis; Basilis Agrogiannis
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.